Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 3/20 | 0.46 |
| ▸ | GABRB2 | P47870 | 3/20 | 0.46 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.40 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.38 |
| ▸ | MGLL | Q99685 | 1/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.37 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.36 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11717665 | 0.87 | IDO1 (0.38) | GABRA1GABRB2HCRTR1HCRTR2L3MBTL1 | |
| SCHEMBL18560070 | 0.82 | AR (0.36) | GABRA1GABRB2PDK2HCRTR1HCRTR2 | |
| SCHEMBL10019111 | 0.80 | GABRA1 (0.37) | GABRA1GABRB2PDK2PTPN5HCRTR1 | |
| SCHEMBL25425763 | 0.79 | GABRA1 (0.58) | GABRA1GABRB2MGLLMAPTNPSR1 | |
| SCHEMBL36294 | 0.79 | GABRA1 (0.58) | GABRA1GABRB2MGLLMAPTNPSR1 | |
| SCHEMBL29390847 | 0.79 | GABRA1 (0.58) | GABRA1GABRB2MGLLMAPTNPSR1 | |
| SCHEMBL6685032 | 0.78 | RIPK1 (0.48) | GABRA1GABRB2MGLLMAPTNPSR1 | |
| SCHEMBL18882522 | 0.77 | GABRA1 (0.43) | GABRA1GABRB2PDK2PTPN5MGLL | |
| SCHEMBL9742072 | 0.77 | HCRTR1 (0.30) | GABRA1GABRB2HCRTR1HCRTR2 | |
| SCHEMBL9742022 | 0.77 | OPRM1 (0.32) | GABRA1GABRB2HCRTR1HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240025918-A1 | KRAS G12D Inhibitors | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2024-01-25 | — | — | US | disclosed |
| US-20210139477-A1 | ALK5 INHIBITORS, CONJUGATES, AND USES THEREOF | SILVERBACK THERAPEUTICS, INC. | 2021-05-13 | — | — | US | disclosed |
| WO-2021023247-A1 | KRAS MUTANT PROTEIN INHIBITOR | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2021-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210139477-A1 | ALK5 INHIBITORS, CONJUGATES, AND USES THEREOF | ALK, ALKBH5, ACVR1 | GABRA1 2760/4885GABRB2 3351/4885PDK2 4022/4885 |
| US-20240025918-A1 | KRAS G12D Inhibitors | KRAS, NRAS, HRAS | GABRA1 3975/4885GABRB2 4007/4885PDK2 2156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.